Literature DB >> 28336088

Trends in ADHD medication use in children and adolescents in five western countries, 2005-2012.

Christian J Bachmann1, Linda P Wijlaars2, Luuk J Kalverdijk3, Mehmet Burcu4, Gerd Glaeske5, Catharina C M Schuiling-Veninga6, Falk Hoffmann7, Lise Aagaard8, Julie M Zito9.   

Abstract

Over the last two decades, the use of ADHD medication in US youth has markedly increased. However, less is known about ADHD medication use among European children and adolescents. A repeated cross-sectional design was applied to national or regional data extracts from Denmark, Germany, the Netherlands, the United Kingdom (UK) and the United States (US) for calendar years 2005/2006-2012. The prevalence of ADHD medication use was assessed, stratified by age and sex. Furthermore, the most commonly prescribed ADHD medications were assessed. ADHD medication use prevalence increased from 1.8% to 3.9% in the Netherlands cohort (relative increase: +111.9%), from 3.3% to 3.7% in the US cohort (+10.7%), from 1.3% to 2.2% in the German cohort (+62.4%), from 0.4% to 1.5% in the Danish cohort (+302.7%), and from 0.3% to 0.5% in the UK cohort (+56.6%). ADHD medication use was highest in 10-14-year olds, peaking in the Netherlands (7.1%) and the US (8.8%). Methylphenidate use predominated in Europe, whereas in the US amphetamines were nearly as common as methylphenidate. Although there was a substantially greater use of ADHD medications in the US cohort, there was a relatively greater increase in ADHD medication use in youth in the four European countries. ADHD medication use patterns in the US differed markedly from those in western European countries.
Copyright © 2017 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Keywords:  Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Methylphenidate; Pharmacoepidemiology

Mesh:

Substances:

Year:  2017        PMID: 28336088     DOI: 10.1016/j.euroneuro.2017.03.002

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  23 in total

1.  ADHD in Germany: Trends in Diagnosis and Pharmacotherapy.

Authors:  Christian J Bachmann; Alexandra Philipsen; Falk Hoffmann
Journal:  Dtsch Arztebl Int       Date:  2017-03-03       Impact factor: 5.594

2.  Attention-Deficit/Hyperactivity Disorder Medication and Unintentional Injuries in Children and Adolescents.

Authors:  Laura Ghirardi; Henrik Larsson; Zheng Chang; Qi Chen; Patrick D Quinn; Kwan Hur; Robert D Gibbons; Brian M D'Onofrio
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2019-07-11       Impact factor: 8.829

3.  Co-occurring medical and behavioural conditions in children with Down syndrome with or without ADHD symptom presentation.

Authors:  A J Esbensen; L B Vincent; J N Epstein; K Kamimura-Nishimura; S Wiley; K Angkustsiri; L Abbeduto; D Fidler; J S Anixt; T E Froehlich
Journal:  J Intellect Disabil Res       Date:  2021-12-23

4.  Relative Age Effect in Attention Deficit/Hyperactivity Disorder at Various Stages of the Medicalization Process.

Authors:  Marie-Christine Brault; Emma Degroote; Mireille Jean; Mieke Van Houtte
Journal:  Children (Basel)       Date:  2022-06-15

5.  Pharmacokinetic and pharmacodynamic analysis of d-amphetamine in an attention task in rodents.

Authors:  Jonathan M Slezak; Melanie Mueller; George A Ricaurte; Jonathan L Katz
Journal:  Behav Pharmacol       Date:  2018-09       Impact factor: 2.293

6.  How Realistic Are the Scientific Assumptions of the Neuroenhancement Debate? Assessing the Pharmacological Optimism and Neuroenhancement Prevalence Hypotheses.

Authors:  Stephan Schleim; Boris B Quednow
Journal:  Front Pharmacol       Date:  2018-01-22       Impact factor: 5.810

7.  Mining Patients' Narratives in Social Media for Pharmacovigilance: Adverse Effects and Misuse of Methylphenidate.

Authors:  Xiaoyi Chen; Carole Faviez; Stéphane Schuck; Agnès Lillo-Le-Louët; Nathalie Texier; Badisse Dahamna; Charles Huot; Pierre Foulquié; Suzanne Pereira; Vincent Leroux; Pierre Karapetiantz; Armelle Guenegou-Arnoux; Sandrine Katsahian; Cédric Bousquet; Anita Burgun
Journal:  Front Pharmacol       Date:  2018-05-24       Impact factor: 5.810

8.  To Overcome Psychiatric Patients' Mind-Brain Dualism, Reifying the Mind Won't Help.

Authors:  Stephan Schleim
Journal:  Front Psychiatry       Date:  2020-06-30       Impact factor: 4.157

9.  Prescription patterns and medication adherence in preadolescent children with attention deficit hyperactivity disorder.

Authors:  Ajita S Nayak; Hrishikesh Bipin Nachane; Prerna Keshari; Shubhangi R Parkar; Kumar Hemant Saurabh; Manan Arora
Journal:  Indian J Psychiatry       Date:  2021-06-17       Impact factor: 1.759

Review 10.  Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies.

Authors:  Ole Jakob Storebø; Nadia Pedersen; Erica Ramstad; Maja Lærke Kielsholm; Signe Sofie Nielsen; Helle B Krogh; Carlos R Moreira-Maia; Frederik L Magnusson; Mathilde Holmskov; Trine Gerner; Maria Skoog; Susanne Rosendal; Camilla Groth; Donna Gillies; Kirsten Buch Rasmussen; Dorothy Gauci; Morris Zwi; Richard Kirubakaran; Sasja J Håkonsen; Lise Aagaard; Erik Simonsen; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2018-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.